Psychobiotics’ potential

The power of psychobiotics on the Gut-Brain axis

Psychobiotic is a term used in preliminary research to refer to live bacteria that, when ingested in appropriate amounts, might confer a mental health benefit by affecting the microbiota of the host organism. That is to say probiotics with benefits on mental health, including probiotics with a positive impact on stress, anxiety-like, depressive-like symptoms, and sleep.

Psychobiotics might help with mental disorders

The benefits of probiotics for the BGA are described in several studies and meta-analyses for their effect on mood, anxiety, depression and early-life stress. A recently published meta-analysis looked at 27 probiotic or symbiotic interventions and showed a significant improvement in depression and anxiety [Liu 2019]. It is important to note that the benefits are not homogeneous for all the probiotics tested, but are strain-dependent, which is the case for most of the beneficial effects of probiotics.

What is the current state of research on probiotics in the Gut-Brain axis?

The clinical research on mental health is very heterogeneous, given that stress is a risk factor and a consequence of many modern diseases. This heterogeneity is why research is conducted on a variety of people: healthy people as well as people suffering from depression, chronic diseases, or neurodegenerative diseases, and aging people. Some conditions, such as Parkinson’s disease, have promising preclinical data but no clinical study results at present.

Overview of clinical outcomes on probiotics in the gut brain axis

On-going clinical studies on psychobiotics

From 2010 to March 2021, 85 clinical trials targeting the BGA with probiotics were registered.

Currently, the most frequent areas studied are depression, stress, and anxiety, but other areas include severe depression, cognition, autism, and neurodegenerative disorders such as Parkinson’s disease. The techniques associated with these studies are also evolving. Researchers use professionally validated questionnaires and biomarkers such as cortisol, as well as brain imaging, which reveals the regions of the brain being stimulated and what this means. Research teams are also exploring ways to study the brain without using invasive techniques. We estimate that 42% of ongoing research is funded by private companies. This shows that both academia and private industry are investing in this research and working collaboratively.

Registered clinical studies on psychobiotics